Abstract
The genomic characterization of solid tumors and a rapidly growing repertoire of target drugs are revolutionizing cancer treatment. Next-generation sequencing (NGS) panels are progressively used in clinical practice for target therapy in high-income countries. In contrast, limited access to tumor sequencing, among other barriers, precludes precision cancer treatment in low- and middle-income countries. To build towards the implementation of precision oncology in Chile and Latin America, we designed a 25-gene panel that contains predictive biomarkers for currently or near-future available therapies in Latin America. Library preparation was optimized to account for DNA integrity variability in Formalin-Fixed Paraffin-Embedded (FFPE) tissue. The bioinformatic pipeline removes FFPE-induced artifacts and known germline variants; while identifying possible discrepancies in somatic mutations due to Latin Americans’ underrepresentation in the reference genome databases. Analytic sensitivity and accuracy were assessed using commercial standard controls for FFPE DNA and for germline BRCA1 and BRCA2 mutations, which are biomarkers for PARP inhibitors. Our panel detects small insertions and deletions and single nucleotide variants (SNVs) with 100% sensitivity and specificity down to allelic frequencies of 0.05, and with 100% between-run and within-run reproducibility for non-synonymous variants. The workflow was validated in 265 clinical samples, including breast, colorectal, gastric, ovarian, and gallbladder tumors and blood, leading to identifying 131 actionable variants. Therefore, this NGS panel constitutes an accurate and sensitive method for routine tumor biopsies that could replace multiple non-NGS assays and costly large NGS panels in the Latin American clinical context. The proposed streamlined assay and automated analysis are expected to facilitate the implementation of precision medicine in Latin America.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by grant FONDEF IDEA IT16I10051. The HPC computational resources used in this work were funded by grants VID INFRAESTRUCTURA 0440/2018 (University of Chile), FONDEF D10E1007 and D11I1029 (CONICYT), and VID U-Redes 704/2016 (University of Chile), FONDECYT Fondo Nacional de Investigacion y Tecnologia 1171463. Probes and other consumables were partially provided by Roche Sequencing Solutions (Pleasanton, CA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Comite de Etica Cientifico del Servicio Metropolitano de Salud Oriente, Comite Etico Cientifico o de Investigacion del Hospital Clinico de la Universidad de Chile (approval number Number 17-18), and the Comite de Etica de Investigacion en Seres Humanos de la Facultad de Medicina de la Universidad de Chile.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The bioinformatic pipeline, user manual, and tutorials will be available after publication in the GitHub repository called Pipeline-TumorSec (https://github.com/u-genoma/Pipeline-TumorSec). The pipeline is available in a docker image (https://hub.docker.com/repository/docker/labgenomicatumorsec/tumorsec).
https://github.com/u-genoma/Pipeline-TumorSec
https://hub.docker.com/repository/docker/labgenomicatumorsec/tumorsec
